Compare Cintas Corporation (CTAS) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Nuwellis Inc — how do they compare? Cintas Corporation trades at $200.75 (market cap $78.78B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: Cintas Corporation is far larger — about 35809.1× Nuwellis Inc's market cap, and Cintas Corporation pays a 1.05% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cintas Corporation for 124 Days and Nuwellis Inc for 26 Days on average.
| CTAS | NUWE | |
|---|---|---|
Market Cap | $78.78B | $2.20M |
Volume | 1,620,783 | 121,544 |
Sector | Industrials | Health |
52-Week High | $216.53 | $146.65 |
52-Week Low | $163.55 | $0.68 |
Typical Hold Time | 124 Days | 26 Days |
Enterprise Value | $81.25B | -$1.52M |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $197.19, up 0.63% on the day, with a bullish technical signal and strong fundamental performance. Recent Q1 2027 earnings beat expectations with revenue of $3.01 billion and EPS of $1.39, driven by organic growth and margin expansion. The company raised fiscal 2027 guidance, reflecting confidence in continued momentum. Valuation multiples remain elevated with a P/E of 38.89, supported by robust profitability metrics including a 17.82% net income margin and 42.08% ROE.
The outlook for CTAS is positive, with earnings growth and raised guidance serving as key catalysts for potential upside toward the consensus price target of $234.60. Risks include high valuation sensitivity to growth sustainability and competitive pressures in the uniform rental sector. Analyst sentiment is moderately bullish, with 40% buy ratings, but investors should monitor execution against elevated expectations.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
